ArticleJournal of enzyme inhibition and medicinal chemistry2021
Inhibitory evaluation of
Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Phloridzin's Diabetic Wound Healing Potential through DPP-4 Enzyme Inhibition: A Review Article.Current diabetes reviews · 2025Review
- Structural Characterization and In Vitro and In Silico Studies on the Anti-Foods (Basel, Switzerland) · 2024Article
- Study of the antidiabetic mechanism of berberine compound on FOXO1 transcription factor through molecular docking and molecular dynamics simulations.Journal of molecular modeling · 2024Article
- A comprehensiveFrontiers in pharmacology · 2024Review
- An Investigation into the Phytochemical Content and Antioxidant, Antidiabetic, and Wound-Healing Activities ofTheScientificWorldJournal · 2024Article
- Cheminformatics identification of modulators of key carbohydrate-metabolizing enzymes fromJournal of diabetes and metabolic disorders · 2023Article
- Berberine and Its Study as an Antidiabetic Compound.Biology · 2023Review
- Drug Repurposing of FDA Compounds against α-Glucosidase for the Treatment of Type 2 Diabetes: Insights from Molecular Docking and Molecular Dynamics Simulations.Pharmaceuticals (Basel, Switzerland) · 2023Article
- A Review ofMolecules (Basel, Switzerland) · 2023Review
- Pharmacognostical and Phytochemical Studies and Biological Activity ofTheScientificWorldJournal · 2023Article
- Pharmacological and Clinical Studies of Medicinal Plants That Inhibit Dipeptidyl Peptidase-IV.Drug design, development and therapy · 2023Review
- Molecular docking analysis of tetracyclic triterpenoids fromBioinformation · 2022Article
- A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity.Frontiers in endocrinology · 2022Review
- Identification of Flavonoid C-Glycosides as Promising Antidiabetics Targeting Protein Tyrosine Phosphatase 1B.Journal of diabetes research · 2022Article
- Advanced Bioinformatics Tools in the Pharmacokinetic Profiles of Natural and Synthetic Compounds with Anti-Diabetic Activity.Biomolecules · 2021Review
- Phenolics Profiling ofMolecules (Basel, Switzerland) · 2021Article
- Phytochemistry and Pharmacological Activity of Plants of GenusMolecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inhibition of α-glucosidase and DPP enzymes capable of effectively reducing blood glucose level in the management of type 2 diabetes. The purpose of the present study is to evaluate the inhibitory potential of α-glucosidase and DPP (IV) activity including with the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.